Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer

NCT02980341 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT02980341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02980341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2, Multicenter, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
November 28, 2016
Completion date
September 7, 2023
Enrollment
182 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer